FDPS, farnesyl diphosphate synthase, 2224

N. diseases: 83; N. variants: 3
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C4225262
Disease: POROKERATOSIS 9, MULTIPLE TYPES
POROKERATOSIS 9, MULTIPLE TYPES
0.700 Biomarker disease GENOMICS_ENGLAND Mutations in the mevalonate pathway genes in Chinese patients with porokeratosis. 27422687 2016
CUI: C4225262
Disease: POROKERATOSIS 9, MULTIPLE TYPES
POROKERATOSIS 9, MULTIPLE TYPES
0.700 GeneticVariation disease UNIPROT Genomic variations of the mevalonate pathway in porokeratosis. 26202976 2015
CUI: C4225262
Disease: POROKERATOSIS 9, MULTIPLE TYPES
POROKERATOSIS 9, MULTIPLE TYPES
0.700 Biomarker disease GENOMICS_ENGLAND Genomic variations of the mevalonate pathway in porokeratosis. 26202976 2015
CUI: C4225262
Disease: POROKERATOSIS 9, MULTIPLE TYPES
POROKERATOSIS 9, MULTIPLE TYPES
0.700 CausalMutation disease CLINVAR
CUI: C4225262
Disease: POROKERATOSIS 9, MULTIPLE TYPES
POROKERATOSIS 9, MULTIPLE TYPES
0.700 Biomarker disease CTD_human
Porokeratosis, Disseminated Superficial Actinic
0.300 GermlineCausalMutation disease ORPHANET Genomic variations of the mevalonate pathway in porokeratosis. 26202976 2015
CUI: C0162839
Disease: Porokeratosis
Porokeratosis
0.110 Biomarker disease BEFREE Mutation of four genes in this pathway, including mevalonate kinase, phosphomevalonate kinase, mevalonate diphosphate decarboxylase and farnesyl diphosphate synthase, have demonstrated to be responsible for porokeratosis (PK). 28765912 2017
CUI: C0162839
Disease: Porokeratosis
Porokeratosis
0.110 Biomarker disease HPO
CUI: C0007137
Disease: Squamous cell carcinoma
Squamous cell carcinoma
0.100 Biomarker disease HPO
CUI: C0033774
Disease: Pruritus
Pruritus
0.100 Biomarker phenotype HPO
CUI: C0349506
Disease: Photosensitivity of skin
Photosensitivity of skin
0.100 Biomarker phenotype HPO
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.060 AlteredExpression group BEFREE We evaluated the FDPS expression and its cancer-associated phenotypes using in vitro and in vivo methods in PTEN-deficient and sufficient human and mouse PCa cells and tumors. 30914801 2019
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.060 Biomarker group BEFREE A slow dissociation inhibition pattern and a noncompetitive allosteric binding mode were found, and cellular mechanism-of-action studies showed that these inhibitors inhibit tumor cell growth primarily by inhibiting <i>Hs</i>FPPS, leading to downregulation of Ras prenylation and cell apoptosis. 31725297 2019
CUI: C0029456
Disease: Osteoporosis
Osteoporosis
0.060 GeneticVariation disease BEFREE From January 2014 to March 2018, a retrospective study of 88 patients with spondylolisthesis and osteoporosis treated with minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF) using the conventional pedicle screw (CPS group, n = 52) and the fenestrated pedicle screw (FPS group, n = 36) was performed with a follow-up of 30 months (range, 10-58 months). 31279300 2019
CUI: C0029456
Disease: Osteoporosis
Osteoporosis
0.060 GeneticVariation disease BEFREE Our study showed a strong association between bone mineral density and polymorphisms in the FDPS gene, and a borderline association with LRP5 and SOST polymorphisms in postmenopausal Romanian women with osteoporosis.No association was found for VKORC1. 31774873 2019
CUI: C0029456
Disease: Osteoporosis
Osteoporosis
0.060 Biomarker disease BEFREE Bisphosphonates (BPs), referred to as gold standard for osteoporosis treatment, have well established role in attenuation of bone resorption and osteoclast apoptosis by inhibition of farnesyl pyrophosphate synthase enzyme (FPPS) in mevalonate pathway. 30096489 2018
CUI: C0029456
Disease: Osteoporosis
Osteoporosis
0.060 Biomarker disease BEFREE FPS-ZM1 can rescue the negative effects of AGEs and provide a possible treatment for bone tissue regeneration in patients with diabetic osteoporosis. 30014569 2018
CUI: C0029456
Disease: Osteoporosis
Osteoporosis
0.060 Biomarker disease BEFREE These results suggest that FDPS is important for the maintenance of glioblastoma stemness and that alendronate, a drug widely used to treat osteoporosis, can be repositioned to treat glioblastoma. 30333528 2018
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.060 AlteredExpression group BEFREE Interestingly, compared to tumor-free peripheral (TFB) brain and normal human astrocytes (NHA), FDPS protein expression and enzyme activity were detected at high degree in tumor mass where a correlation with canonical oncogenic signaling pathways such as STAT3, ERK and AKT was also documented. 29075041 2017
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.060 Biomarker group BEFREE To test the combined inhibition of RAGE in both tumor cell-intrinsic and non-tumor cells of the microenvironment, we performed in vivo treatment of xenografted tumors with FPS-ZM1 (1 mg/kg, two times per week). 27669433 2017
CUI: C0029456
Disease: Osteoporosis
Osteoporosis
0.060 GeneticVariation disease BEFREE Association of farnesyl diphosphate synthase polymorphisms and response to alendronate treatment in Chinese postmenopausal women with osteoporosis. 24534219 2014
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.060 Biomarker group BEFREE FPS-1 cells showed the same morphological and immunophenotypical characteristics as the primary tumor. 17094458 2006
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.060 AlteredExpression group BEFREE The incomplete penetrance of the neoplastic phenotype and the monoclonality of lymphoid tumors suggest that tumor formation in v-fps mice requires genetic or epigenetic events in addition to expression of the P130gag-fps protein-tyrosine kinase. 2555699 1989
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.050 Biomarker group BEFREE Experimental results revealed that VS-4 could better target the FPPS high-expressing colon LoVo and HCT116 cancer cell lines with IC<sub>50</sub> of 51.772 ± 0.473 and 43.553 ± 1.027 μM, respectively, whereas the IC<sub>50</sub> value against FPPS low expressing MDA-MB-231 cells was >100 μM. 31785819 2020
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.050 Biomarker group BEFREE Experimental results revealed that VS-4 could better target the FPPS high-expressing colon LoVo and HCT116 cancer cell lines with IC<sub>50</sub> of 51.772 ± 0.473 and 43.553 ± 1.027 μM, respectively, whereas the IC<sub>50</sub> value against FPPS low expressing MDA-MB-231 cells was >100 μM. 31785819 2020